我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
1
50.0%
尚未招募
暂无批准数据
- Cuba has initiated a Phase II-III clinical trial to assess the safety, immunogenicity, and efficacy of a new 11-valent pneumococcal vaccine, Quimio-Vio, in adults aged 50-74. - The trial aims to expand the availability of pneumococcal vaccination to the adult population, addressing the high morbidity and mortality associated with pneumococcal diseases in older adults. - The study will involve approximately 1,000 volunteers and, if successful, will lead to an application for sanitary registration to make the vaccine available nationwide. - Previous trials of the 7-valent Quimi-Vio vaccine in children have shown a good safety profile and significant reductions in respiratory disease and invasive pneumococcal disease.
